clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Arthritis D001168 41 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Abscess D000038 13 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Heart Failure D006333 36 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Fibrosis D005355 23 associated lipids
Tooth Discoloration D014075 7 associated lipids
Sinusitis D012852 9 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Cross Infection D003428 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Wound Infection D014946 12 associated lipids
Bacteriuria D001437 7 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Periodontal Pocket D010514 9 associated lipids
Ischemia D007511 18 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Periodontitis D010518 22 associated lipids
Nasal Polyps D009298 26 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Dermatomycoses D003881 17 associated lipids
Fever D005334 35 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Bronchial Spasm D001986 18 associated lipids
Hyperlipidemias D006949 73 associated lipids
Bronchitis D001991 6 associated lipids
Shock, Septic D012772 11 associated lipids
Iritis D007500 2 associated lipids
Syphilis D013587 6 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Hearing Disorders D006311 10 associated lipids
Duodenitis D004382 4 associated lipids
Metaplasia D008679 7 associated lipids
Foot Diseases D005534 4 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Radiation Injuries D011832 14 associated lipids
Urticaria D014581 13 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
HIV Seropositivity D006679 15 associated lipids
Endophthalmitis D009877 12 associated lipids
Leprosy D007918 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Paronychia D010304 3 associated lipids
Dyspnea D004417 10 associated lipids
Pyelonephritis D011704 5 associated lipids
Angina Pectoris D000787 27 associated lipids
Klebsiella Infections D007710 7 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Choi SJ et al. Column-switching high-performance liquid chromatographic determination of clarithromycin in human plasma with electrochemical detection. 2001 Talanta pmid:18968261
Li W et al. Determination of clarithromycin in rat plasma by HPLC-UV method with pre-column derivatization. 2007 Talanta pmid:19071316
Vu DH et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. 2014 Talanta pmid:24607103
Moayyedi P and Murphy B Helicobacter pylori: a clinical update. 2001 Symp Ser Soc Appl Microbiol pmid:11422568
Kusters JG and Kuipers EJ Antibiotic resistance of Helicobacter pylori. 2001 Symp Ser Soc Appl Microbiol pmid:11422569
Schulzke S et al. Mycobacterium bohemicum--a cause of paediatric cervical lymphadenitis. 2004 Swiss Med Wkly pmid:15190440
Piso RJ et al. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters. 2013 Swiss Med Wkly pmid:24089030
Wang B et al. In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates. Swiss Med Wkly pmid:30044468
Soltermann A et al. Assessment of Helicobacter pylori clarithromycin resistance mutations in archival gastric biopsy samples. 2005 Swiss Med Wkly pmid:16034687
Cone LA et al. Delirium in the elderly resulting from azithromycin therapy. 2003 Surg Neurol pmid:12826358
Nzeako BC and Al-Namaani F The antibacterial activity of honey on helicobacter pylori. 2006 Sultan Qaboos Univ Med J pmid:21748138
Lee HY et al. Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. 2012 Subst Abuse Treat Prev Policy pmid:22429858
Earl AM et al. High quality draft genome sequence of Segniliparus rugosus CDC 945(T)= (ATCC BAA-974(T)). 2011 Stand Genomic Sci pmid:22675588
Sikorski J et al. Complete genome sequence of Segniliparus rotundus type strain (CDC 1076). 2010 Stand Genomic Sci pmid:21304703
Lotfy HM and Abdel-Monem Hagazy M Comparative study of novel spectrophotometric methods manipulating ratio spectra: an application on pharmaceutical ternary mixture of omeprazole, tinidazole and clarithromycin. 2012 Spectrochim Acta A Mol Biomol Spectrosc pmid:22683662
Ahmed S and Atia NN Simultaneous determination of triple therapy for Helicobacter pylori in human plasma by reversed phase chromatography with online wavelength switching. 2015 Spectrochim Acta A Mol Biomol Spectrosc pmid:25459696
Sadeghifard N et al. Survey in Iran of clarithromycin resistance in Helicobacter pylori isolates by PCR-RFLP. 2013 Southeast Asian J. Trop. Med. Public Health pmid:23682442
Kumala W and Rani A Patterns of Helicobacter pylori isolate resistance to fluoroquinolones, amoxicillin, clarithromycin and metronidazoles. 2006 Southeast Asian J. Trop. Med. Public Health pmid:17333742
Iamsawat S et al. Multiplex PCR for detection of clarithromycin resistance and simultaneous species identification of Mycobacterium avium complex. 2010 Southeast Asian J. Trop. Med. Public Health pmid:20578547
Waites K et al. In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment. 1997 South. Med. J. pmid:9191739
Krishna M and Lalmuanpuii J Helicobacter pylori treatment. 2005 South. Med. J. pmid:16351026
Gurbuz AK et al. Effect of N-acetyl cysteine on Helicobacter pylori. 2005 South. Med. J. pmid:16351030
Kanbay M et al. Hyponatremia due to an additive effect of carbamazepine and clarithromycin. 2007 South. Med. J. pmid:17330699
Ermis F et al. Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. 2011 South. Med. J. pmid:21886067
Bégué RE et al. Effect of Helicobacter pylori eradication in the glycemia of children with type 1 diabetes: a preliminary study. 2002 South. Med. J. pmid:12190218
Nadir I et al. Comparison of two different treatment protocols in Helicobacter pylori eradication. 2011 South. Med. J. pmid:21206418
Knower MT et al. Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients. 2000 South. Med. J. pmid:11095559
Asnis DS et al. Mycobacterium avium-intracellulare complex pneumonia in a non-HIV-infected individual: an increasingly recognized disease. 1996 South. Med. J. pmid:8638183
Demir M et al. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. 2009 South. Med. J. pmid:19864973
Cheng VC et al. Two probable cases of serious drug interaction between clarithromycin and colchicine. 2005 South. Med. J. pmid:16144178
Randhawa K et al. Nine-year progression of untreated pulmonary Mycobacterium szulgai infection. 2010 South. Med. J. pmid:20622732
Singh V et al. Vesicular palmoplantar pityriasis rosea. 2012 Mar-Apr Skinmed pmid:22545332
Bernstein JM and Bacheller CD It's on the tip of my tongue. Skinmed pmid:16687984
Alberts JH and Boyd AS Nocardia otitidiscaviarum: an unusual Nocardia species causing a primary lymphocutaneous infectious process in a mildly immunosuppressed patient. 2002 Sep-Oct Skinmed pmid:14673241
Ling KL et al. Efficacy of a nitroimidazole containing tripletherapy regime in Singapore. 2001 Singapore Med J pmid:11599627
Luman W et al. One week triple therapy for Helicobacter pylori associated duodenal ulcer disease. 1999 Singapore Med J pmid:10709423
Zainal Muttakin AR and Tan AM Mycobacterium fortuitum catheter-related sepsis in acute leukaemia. 2006 Singapore Med J pmid:16752025
Chew CA et al. The diagnosis and management of H. pylori infection in Singapore. 2017 Singapore Med J pmid:28536725
Khor CJ et al. Recurrence of Helicobacter pylori infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population. 2000 Singapore Med J pmid:11256345
Goh IX et al. Cytochrome P450 drug interactions with statin therapy. 2013 Singapore Med J pmid:23546024
Fock KM et al. A randomised trial of amoxycillin versus clarithromycin in combination with omeprazole for eradication of Helicobacter pylori infection in Singapore. 2000 Singapore Med J pmid:11281438
Mak SK et al. A retrospective study on efficacy of proton-pump inhibitor-based triple therapy for eradication of Helicobacter pylori in patients with chronic renal failure. 2003 Singapore Med J pmid:14503780
Prime K and French P Neuropsychiatric reaction induced by clarithromycin in a patient on highly active antiretroviral therapy (HAART). 2001 Sex Transm Infect pmid:11463936
Colebunders R and Florence E Neuropsychiatric reaction induced by clarithromycin. 2002 Sex Transm Infect pmid:11872875
Zheng H et al. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure. 2015 Sex Transm Dis pmid:25668641
Abu-Khalaf N et al. The Taste of Commercially Available Clarithromycin Oral Pharmaceutical Suspensions in the Palestinian Market: Electronic Tongue and In Vivo Evaluation. 2018 Sensors (Basel) pmid:29401675
Kobayashi Y et al. Advanced taste sensors based on artificial lipids with global selectivity to basic taste qualities and high correlation to sensory scores. 2010 Sensors (Basel) pmid:22319306
Dimopoulos MA et al. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. 2003 Semin. Oncol. pmid:12720150
Coleman M et al. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. 2003 Semin. Oncol. pmid:12720151
Hoffman JS Pharmacological therapy of Helicobacter pylori infection. 1997 Semin. Gastrointest. Dis. pmid:9232728
Miehlke S et al. Treatment of Helicobacter pylori infection. 2001 Semin. Gastrointest. Dis. pmid:11478749
Terkeltaub RA Colchicine update: 2008. 2009 Semin. Arthritis Rheum. pmid:18973929
Moskowitz RW et al. Open-label study of clarithromycin in patients with undifferentiated connective tissue disease. 2006 Semin. Arthritis Rheum. pmid:17023256
Mateo L et al. Mycobacterium chelonae tenosynovitis of the hand. 2004 Semin. Arthritis Rheum. pmid:15609266
Liang J et al. [Analysis of the key intermediates for the regioselectivity control in the methylation of the manufacture of clarithromycin by reversed-phase high performance liquid chromatography]. 2004 Se Pu pmid:15712906
Velu PP et al. Pulmonary Mycobacterium marinum infection: 'fish tank granuloma' of the lung. 2016 Scott Med J pmid:27872397
Cadwgan AM et al. Neisseria meningitidis W135 pneumonia with sepicaemia in a nonogenarian. 1998 Scott Med J pmid:9854302
Isidori M et al. Toxic and genotoxic evaluation of six antibiotics on non-target organisms. 2005 Sci. Total Environ. pmid:15993685
Göbel A et al. Fate of sulfonamides, macrolides, and trimethoprim in different wastewater treatment technologies. 2007 Sci. Total Environ. pmid:17126383
Buchicchio A et al. Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD). 2016 Sci. Total Environ. pmid:27039063
Al Aukidy M et al. Monitoring release of pharmaceutical compounds: occurrence and environmental risk assessment of two WWTP effluents and their receiving bodies in the Po Valley, Italy. 2012 Sci. Total Environ. pmid:22967493
Topp E et al. Reduced persistence of the macrolide antibiotics erythromycin, clarithromycin and azithromycin in agricultural soil following several years of exposure in the field. 2016 Sci. Total Environ. pmid:27096634
Spongberg AL and Witter JD Pharmaceutical compounds in the wastewater process stream in Northwest Ohio. 2008 Sci. Total Environ. pmid:18396321
Feng L et al. Removal of antibiotics during the anaerobic digestion of pig manure. 2017 Sci. Total Environ. pmid:28628813
Karaolia P et al. Reduction of clarithromycin and sulfamethoxazole-resistant Enterococcus by pilot-scale solar-driven Fenton oxidation. 2014 Sci. Total Environ. pmid:24012892
Ratzinger F et al. Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. 2014 Sci Rep pmid:25500904
Bruhn DF et al. In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. 2015 Sci Rep pmid:26365087
Vliegenthart AD et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. 2015 Sci Rep pmid:26489516
Arora S et al. Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for h. Pylori. Sci Pharm pmid:21886911
Kobler E et al. [Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease]. 1997 Schweiz Med Wochenschr Suppl pmid:9289833
Sieber CC et al. [Helicobacter pylori resistance against metronidazole in Switzerland: implications for eradication therapy?]. 1994 Schweiz Med Wochenschr pmid:8091165
Lõivukene K et al. Metronidazole and clarithromycin susceptibility and the subtypes of vacA of Helicobacter pylori isolates in Estonia. 2000 Scand. J. Infect. Dis. pmid:10716079
Edlund C et al. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. 2000 Scand. J. Infect. Dis. pmid:10716083
Dionisio D et al. Encephalitis caused directly by Mycoplasma pneumoniae. 1999 Scand. J. Infect. Dis. pmid:10576133
Hakawi AM and Alrajhi AA Septic arthritis due to Mycobacterium szulgai in a patient with human immunodeficiency virus: case report. 2005 Scand. J. Infect. Dis. pmid:15849060
Barzilai A et al. Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. 1998 Scand. J. Infect. Dis. pmid:9730300
Davies BS et al. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London. 2012 Scand. J. Infect. Dis. pmid:23078529
Inoue H et al. Modulation of the human interleukin-12p40 response by a triazole antifungal derivative, itraconazole. 2004 Scand. J. Infect. Dis. pmid:15370674
Kiiveri KM et al. Recurrent endocarditis caused by beta-haemolytic streptococci group B. 2004 Scand. J. Infect. Dis. pmid:15307575
Jakobsson H et al. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. 2007 Scand. J. Infect. Dis. pmid:17701712
Cordtz J and Jensen JS Disseminated Ureaplasma urealyticum infection in a hypo-gammaglobulinaemic renal transplant patient. 2006 Scand. J. Infect. Dis. pmid:17148091
Bodasing N and Kennedy D Moraxella catarrhalis bacteraemia associated with Mycoplasma pneumoniae infection and pneumonia. 2002 Scand. J. Infect. Dis. pmid:12578160
Giamarellos-Bourboulis E et al. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. 2005 Scand. J. Infect. Dis. pmid:15764190
Burkhardt O et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. 2002 Scand. J. Infect. Dis. pmid:12587622
Ghebremichael S et al. Antimycobacterial synergism of clarithromycin and rifabutin. 1996 Scand. J. Infect. Dis. pmid:8893404
Nakamura S et al. Community acquired pneumonia (CAP) caused by Cryptococcus neoformans in a healthy individual. 2005 Scand. J. Infect. Dis. pmid:16308237
Trübel HK et al. Complicated nosocomial pneumonia due to Legionella pneumophila in an immunocompromised child. 2002 Scand. J. Infect. Dis. pmid:12030402
Alfakry H et al. Periodontopathogen- and host-derived immune response in acute coronary syndrome. 2011 Scand. J. Immunol. pmid:21645027
Alfakry H et al. The association of serum neutrophil markers and acute coronary syndrome. 2012 Scand. J. Immunol. pmid:22537345
Götz JM et al. Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. 1995 Scand. J. Gastroenterol. Suppl. pmid:8578230
Williamson R et al. New options in Helicobacter pylori eradication: efficacy, resistance and synergy. 1998 Scand. J. Gastroenterol. Suppl. pmid:9515751
Unge P Review of Helicobacter pylori eradication regimens. 1996 Scand. J. Gastroenterol. Suppl. pmid:8722388
Bazzoli F Italian omeprazole triple therapy--a 1-week regimen. 1996 Scand. J. Gastroenterol. Suppl. pmid:8722395
Sillakivi T et al. An attempt at Helicobacter pylori eradication with intravenous clarithromycin in perforated peptic ulcer patients. 2001 Scand. J. Gastroenterol. pmid:11589389
Ogura K et al. Clarithromycin-based triple therapy for non-resistant Helicobacter pylori infection. How long should it be given? 2001 Scand. J. Gastroenterol. pmid:11424316
Seppälä K et al. Cure of Helicobacter pylori infection in all compliant patients: report on 644 subjects. 2008 Scand. J. Gastroenterol. pmid:18609180
Khan Z et al. Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study. 2002 Scand. J. Gastroenterol. pmid:11843048
Gasbarrini A et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. 2000 Scand. J. Gastroenterol. pmid:10766318
Lerang F et al. Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy. 1997 Scand. J. Gastroenterol. pmid:9438318
Lee JW et al. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. 2014 Scand. J. Gastroenterol. pmid:24957849